lmmunogenicity, reactogenicityan safetystudyof Pediarix, Hiberix, and Prevnar 13 co-administered with two diff'erent formulations of GSK Biologicals' HRVvaccine ( 444563) in healthy infants 6-12 weeks of age

Project: Other project

StatusFinished
Effective start/end date8/18/178/17/19

Funding

  • GlaxoSmithKline Pharmaceuticals: $36,307.16